Indigo Diabetes, a developer of continuous metabolic monitoring devices (CMMTM) using nanophotonic technology, is expanding its US operations with the addition of a wholly owned subsidiary, Indigo Medical, and the appointment of Peter J. Devlin as president of the newly formed subsidiary.

The company is establishing a presence in the US, a market it has identified as having significant potential for its CMM devices.

Devlin, who will be based in Boston, will manage and oversee Indigo Medical’s operations. His focus will be on accelerating product development for the company’s CMM devices, driving business development and facilitating talent acquisition in the US. He will report directly to Danaë Delbeke, CEO of Indigo.

Indigo is developing a fully implantable CMM system for people living with diabetes to access accurate information about their glucose, ketone and lactate levels. The CMM sensor is inserted subcutaneously, eliminating the need for people with diabetes to wear an external device on their body. It is designed to give people living with diabetes and their caregivers immediate access to the advanced metabolic information they need to better manage their diabetes and improve therapeutic decision-making.

Peter J. Devlin, President of Indigo Medical US, said, “I have worked for many years in both in vitro diagnostics and diabetes care and am delighted to join the Indigo team and lead Indigo Medical Inc. The timing is exciting for the Company to establish a presence in the US, especially with the increased focus on the commercial development of our subcutaneous implantable sensor for continuous metabolite monitoring.”

Dr. Danaë Delbeke, CEO, inventor and co-founder of Indigo Diabetes, added: “Peter has worked successfully with us as a strategic advisor over the past year and I am delighted that he has chosen to join us full-time to leads our newly established US subsidiary. This represents a significant market for us and with his extensive experience he will play a vital role in helping us bring our first device to the US and European markets.”

Devlin has over 30 years of experience leading the development and commercialization of medical devices. He has served as a strategic advisor to Indigo over the past year, advising on product development, market access and the diabetes market. Prior to joining Indigo, he worked for several years as an independent director and strategic advisor to early-stage medical technology companies. Previously, he served as Chief Commercial Officer of Insulet Corporation, a US medical device company, where he led sales, marketing, business development, clinical research and customer service operations. While there, he helped develop and commercialize the OmniPod portable insulin delivery system for people living with diabetes, which led the company to over $350 million in annual revenue.